Involvement of ERK pathway in cataract in typeⅡdiabetes and alleviations of PD98059, inhibitor of ERK

Han XIAO,Wen-bin LIU,Li WAN
DOI: https://doi.org/10.3969/j.issn.1003-6350.2015.07.0339
2015-01-01
Abstract:Objective To explore the involvement of ERK pathway in the pathogenesis of typeⅡdiabetic cataract and the interventions of PD98059 (the inhibitor of ERK). Methods Thirty-five male SD rats were divided in-to five groups:control group, diabetic group, low/middle/high dose of PD98059 group (n=7 in each group). The typeⅡdiabetic cataract model was duplicated by low dose of STZ injections combined with high content of fat and sugar diet for 120 d. All the rats were administrated with normal saline or PD98059. The HOMA-IR was calculated in each group. And at the same time, the expression of ERK1/2, p-ERK1/2, p38, ATF6 and PERK were detected by Western blotting or real-time PCR. Results The HOMA-IR in diabetic group was increased greatly with cloudy lens when compared to the control group. The expression of p-ERK1/2, p38, ATF6 and PERK were up-regulated dramatically in diabetic group, while the expression of total ERK has no change. PD98059 alleviated the cloudy lens in diabetic rats significantly and normalized the aforementioned abnormal proteins greatly. Conclusion Activated ERK pathway and endoplasmic reticulum stress are involved in the pathogenesis of cataract in typeⅡdiabetes. PD98059 alleviates the cataract by inhibiting the aforementioned parameters in a dose dependent manner.
What problem does this paper attempt to address?